NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form-2 ...

WHAT'S NEXT? If you suffered a loss in Inspire Medical Systems, Inc. during the relevant time frame, you have until January 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team ...

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information via the provided link or contact the firm directly for further details [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including a notable recovery of over $438 million for investors in 2019 [4]. - Investors are advised that until a class is certified, they are not represented unless they retain counsel, and they have the option to remain absent from the class [7].

Medtronic (MDT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings pictur ...

Core Insights - Becton, Dickinson and Company (BDX) has announced a collaboration with ChemoGLO to enhance hazardous drug contamination testing in healthcare settings, aiming to improve safety for healthcare workers [1][8] Company Developments - The collaboration is a strategic move to strengthen BDX's Medication Delivery Solutions (MDS) business unit within the BD Medical segment [2] - The partnership will integrate BD HD Check System's rapid qualitative results with ChemoGLO's advanced analytical methods, providing comprehensive quantitative reports on hazardous drugs within three to five days [4][5] - BDX's management anticipates that this collaboration will enable quicker identification of contamination risks and enhance understanding of exposure risks [5] Market Performance - Following the announcement, BDX shares increased by nearly 0.1%, with a current market capitalization of $55.54 billion and an earnings yield of 7.7%, surpassing the industry average of 5.8% [3] - Over the past year, BDX shares have decreased by 11.1%, contrasting with an 8% rise in the industry and a 15.3% gain in the S&P 500 [9] Industry Outlook - The global drug screening market is projected to grow from $15.4 billion in 2025 to $52.2 billion in 2034, at a compound annual growth rate (CAGR) of 14.5%, driven by increasing concerns over substance abuse and stricter regulatory requirements [6]

Key Takeaways GEHC and URMC formed a 7-year Care Alliance to expand advanced imaging and monitoring.The alliance targets MRI, CT, PET/CT, SPECT/CT and ultrasound upgrades along with workflow standardization.The partnership boosts GEHC's enterprise reach with unified monitoring and long-term service ties.GE HealthCare (GEHC) and the University of Rochester Medical Center (URMC) entered into a seven-year Care Alliance aimed at expanding advanced imaging, strengthening precision medicine and standardizing pati ...

Core Viewpoint - Cooper Companies reported better-than-expected fourth-quarter earnings and provided optimistic financial guidance, leading to a rise in stock price [1][7] Financial Performance - The company reported fourth-quarter adjusted earnings of $1.15 per share, an 11% increase year over year, surpassing the consensus estimate of $1.11 [2] - Total sales for the quarter were $1.065 billion, nearly matching the consensus of $1.061 billion, reflecting a 5% year-over-year increase and 3% organic growth [2] - The CooperVision segment generated sales of $709.6 million, a 5% increase from the previous year's fourth quarter, with 3% growth in constant currency and organically [3] - CooperSurgical reported revenue of $355.6 million, up 4% year over year, with consistent growth in constant currency and organically [3] Future Outlook - For the first quarter of 2026, the company expects sales between $1.019 billion and $1.030 billion, compared to the consensus of $1.025 billion, with adjusted earnings projected at $1.02 to $1.04 per share against a consensus of $1.00 [4] - The company anticipates organic growth of 3% to 4% for 2026 and adjusted earnings for fiscal 2026 to be between $4.45 and $4.60 per share, exceeding the consensus of $4.09 [4] - Projected sales for fiscal 2026 are estimated to be between $4.299 billion and $4.338 billion, compared to the consensus of $4.089 billion [4] - Free cash flow for fiscal 2026 is expected to be between $575 million and $625 million, with projections of over $2.2 billion in free cash flow from fiscal 2026 to fiscal 2028 [5] Analyst Reactions - Needham maintains a Buy rating and raises the price target from $94 to $100 [6] - Mizuho keeps an Outperform rating and increases the price target from $85 to $100 [6] - Baird maintains an Outperform rating and raises the price target from $85 to $98 [6] - JP Morgan retains a Neutral rating and raises the price target from $66 to $78 [6] - Wells Fargo maintains an Equal-Weight rating and increases the price target from $72 to $82 [6]

Core Viewpoint - Intuitive Surgical (ISRG) stock is considered a worthwhile investment due to high margins and cash generation capabilities, currently available at a discounted price [2]. Company Overview - Intuitive Surgical is the global leader in robotic-assisted surgery, primarily known for its da Vinci surgical system, which enhances precision, efficiency, and safety in minimally invasive procedures, driving recurring revenue through instruments, services, and system upgrades [3]. Recent Performance - ISRG stock has increased by 8.9% year-to-date, while its Price-to-Sales (P/S) ratio is 12% lower compared to one year ago [5]. - In Q3 2025, there was a 20% global increase in procedures, largely due to the adoption of the da Vinci 5 system, with 240 units installed, bringing the total installed base to nearly 10,800 systems [6]. - The company has 85% recurring revenue from instruments and services, ensuring robust cash generation [6]. - Management has raised full-year 2025 procedure growth projections to 17-17.5%, indicating strong demand and pricing power [6]. Financial Metrics - Recent profitability metrics include an operating cash flow margin of 30.8% and an operating margin of 29.3% for the last twelve months [11]. - Long-term profitability metrics show an average operating cash flow margin of approximately 27.8% and an operating margin of 26.7% over the last three years [11]. - Revenue growth for Intuitive Surgical was 22.2% for the last twelve months and 16.3% on a three-year average, although it is not classified as a growth story [11]. - The stock is currently available at a P/S multiple of 16.6, representing a 12% discount compared to one year ago [11]. Investment Criteria - The company meets several investment criteria, including a market cap greater than $10 billion, high cash flow from operations margins, and a significant decline in valuation over the past year [12].

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, ...

Core Viewpoint - SiBone (SIBN) is identified as a potential stock pick due to a recent "golden cross" event, indicating a bullish trend from a technical perspective [1]. Technical Analysis - A "golden cross" occurs when a short-term moving average (50-day) crosses above a long-term moving average (200-day), suggesting a potential bullish breakout [2]. - The formation of a golden cross involves three stages: a downtrend that bottoms out, the crossover of moving averages, and subsequent upward momentum [3]. - The golden cross is contrasted with a "death cross," which indicates potential bearish momentum [3]. Performance Metrics - SIBN has experienced a rally of 26.7% over the past four weeks, indicating strong upward momentum [4]. - Currently, SIBN holds a 3 (Hold) rating on the Zacks Rank, suggesting it may be poised for further breakout [4]. - Earnings expectations for SIBN have improved, with five upward revisions and no downward changes in the last 60 days, leading to an increase in the Zacks Consensus Estimate [4]. Investment Consideration - Given the significant technical indicators and positive earnings estimate movements, SIBN is recommended for inclusion on investors' watchlists [6].